Acerus Pharmaceuticals
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories. Acerus currently has three marketed products: ESTRACE®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; NATESTO®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S.; and URIVARX®, a Natural Health Product that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. URIVARX® was recently approved by Health Canada and will be offered over-the-counter to Canadians dealing with such symptoms. Also, NATESTO® has been licensed for distribution in 29 additional countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. Acerus’ pipeline includes five innovative products: STENDRA®, a new chemical entity PDE5 inhibitor for the treatment of erectile dysfunction, which has been approved by the US FDA and the EU EMA and is commercialized in the US under the trade name STENDRA® and in the EU under the trade name SPEDRA®; ELEGANTTM Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and ELEGANTTM pH, which is a pH balanced vaginal product; GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction. Finally, Acerus is working on expanding its product portfolio by leveraging its proprietary delivery systems, patents and formulation expertise. As such, Acerus has a number of products in various stage of development. One of these projects relates to cannabinoids (whether synthetic or naturally derived cannabinoids) to be delivered intranasally to patients, which may have multiple possible therapeutic applications (the “Cannabinoids Initiative”). Acerus has filed patent applications on the Cannabinoids Initiative, is currently working on setting up a series of pharmacokinetic clinical trials and is actively looking at potential partnering transactions for these initiatives. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP). For more information, visit www.aceruspharma.com.
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories. Acerus currently has three marketed products: ESTRACE®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; NATESTO®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S.; and URIVARX®, a Natural Health Product that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. URIVARX® was recently approved by Health Canada and will be offered over-the-counter to Canadians dealing with such symptoms. Also, NATESTO® has been licensed for distribution in 29 additional countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. Acerus’ pipeline includes five innovative products: STENDRA®, a new chemical entity PDE5 inhibitor for the treatment of erectile dysfunction, which has been approved by the US FDA and the EU EMA and is commercialized in the US under the trade name STENDRA® and in the EU under the trade name SPEDRA®; ELEGANTTM Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and ELEGANTTM pH, which is a pH balanced vaginal product; GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction. Finally, Acerus is working on expanding its product portfolio by leveraging its proprietary delivery systems, patents and formulation expertise. As such, Acerus has a number of products in various stage of development. One of these projects relates to cannabinoids (whether synthetic or naturally derived cannabinoids) to be delivered intranasally to patients, which may have multiple possible therapeutic applications (the “Cannabinoids Initiative”). Acerus has filed patent applications on the Cannabinoids Initiative, is currently working on setting up a series of pharmacokinetic clinical trials and is actively looking at potential partnering transactions for these initiatives. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP). For more information, visit www.aceruspharma.com.
Acerus Pharmaceuticals has raised $2.0M across 1 round. Its most recent round was a Series Unknown of $2.0M in Dec 2022. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Acerus Pharmaceuticals is featured in
Similar companies
Sonic Incytes is a medical device start-up company developing quantitative ultrasound for point-of-care diagnostic and procedure guidance. our mission to enable routine assessment and management of liver health, with diagnostic accuracy you can count on.
MedMe Health is a patient care platform to help pharmacists schedule, conduct, and track clinical services at scale - both virtually and on-site at your pharmacy.
Molecular You provides a detailed analysis of health risks related to conditions like diabetes, Alzheimer's, and heart disease. They also offer personalized health assessments and preventative strategies to help individuals manage their overall health.
BioNxt Solutions is a company that specializes in accelerating advancements in bioscience. They specifically concentrate on creating advanced drug formulations and delivery systems, developing diagnostic screening tests, and producing and assessing new active pharmaceutical ingredients for neurological purposes.
LeoMed is a software company that provides tools for remote monitoring of patients at home.
Cosm Medical is a VC-backed health-tech startup building and commercializing a software-enabled medical device platform to improve the lives of women affected by pelvic floor disorders.
Current Water Technologies Inc. is a leading global company specializing in ammonia treatment in wastewater and electro-static deionization using cost-effective electrochemical technologies. Our AmmEL-H2® system is the most environmentally friendly and financially beneficial ammonia treatment option available, producing green hydrogen and other valuable byproducts. We cater to various industries such as military, mining, aquaculture, municipal water and wastewater treatment, oil and gas, landfill leachate, pharmaceutical, microelectronics, and boiler feedwater. Our patented technologies offer effective alternatives to traditional treatment methods.
Satellos Bioscience is a privately-owned company specializing in regenerative medicine and creating new treatments that stimulate or restore muscle regeneration. The company is working on an oral drug for Duchenne muscular dystrophy that aims to address this issue.
Trusti is dedicated to offering discreet, effective, and convenient at-home rapid STI testing. No need to experience uncomfortable waiting rooms or encounter judgmental receptionists - instead, you can receive your results quickly and easily from the comfort of your own couch, with instant access to our care team.
The Kabila Founder Mental Health Fund is a program that aims to help support the mental health of startup founders in the Kabila community by offering them free mental therapy services. This initiative acknowledges the specific pressures and difficulties that these founders encounter as they navigate their entrepreneurial paths.
Filament Health utilizes advanced extraction and drug discovery techniques to quickly bring natural psychedelics to those in need. The company possesses valuable intellectual property related to natural psychedelics, including innovative methods for extraction and purification.
Tenera is a technology platform that offers hardware, software, and real-time surveillance, as well as analytical tools, to ensure that individuals live safely and healthily. Tenera Care provides enhanced protection within care facilities by tracking the whereabouts of residents, staff, visitors, and assets in both indoor and outdoor environments. It identifies potential dangers and reduces the amount of time it takes to respond to critical incidents.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.